---
layout: default
title: Meloxicam
parent: Model Prediction Only (L5)
nav_order: 360
evidence_level: L5
indication_count: 10
---

# Meloxicam
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Meloxicam: From NSAID Therapy (Original Indication Not Specified in Evidence Pack) to Acromesomelic Dysplasia, Hunter-Thompson Type

## One-Sentence Summary

> Meloxicam's original approved indication(s) are not recorded in this evidence pack, and no marketing authorisation currently exists in this jurisdiction.
> The TxGNN model's top-ranked prediction is **Acromesomelic Dysplasia, Hunter-Thompson Type**,
> but this prediction is supported by **0 clinical trials** and **0 publications**, and the model's own rationale flags it as a likely false positive.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — evidence pack contains no `original_indications` or marketing authorisation records |
| Predicted New Indication | Acromesomelic Dysplasia, Hunter-Thompson Type |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Meloxicam in this evidence pack. Based on general pharmacological class knowledge, Meloxicam is a preferential COX-2 inhibitor within the NSAID class, typically used for inflammatory and pain-related musculoskeletal conditions — but this is not confirmed by data provided here.

Critically, the model's own repurposing rationale for this top-ranked candidate is sceptical rather than supportive. Acromesomelic Dysplasia, Hunter-Thompson Type is a congenital skeletal disorder caused by abnormalities in GDF5 signalling, affecting cartilage development. There is no established biological relationship between this pathway and NSAID/COX inhibition. The evidence pack itself states that this high score is **most likely a knowledge-graph artefact** — a false positive arising from co-occurrence of skeletal/joint-related nodes in the graph, rather than a genuine mechanistic link.

Given the complete absence of supporting clinical trials or literature, and the model's own annotation questioning biological plausibility, this specific prediction should not be interpreted as a credible repurposing signal at this time.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## UK Market Information

Meloxicam currently has no recorded marketing authorisations in this evidence pack (`market_status`: Not marketed; `total_licenses`: 0). No product-level licence data is available to tabulate.

---

## Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (Acromesomelic Dysplasia, Hunter-Thompson Type) has no supporting clinical trials or literature (Evidence Level L5), and the model's own mechanistic rationale explicitly identifies it as a probable false positive driven by knowledge-graph node co-occurrence rather than genuine biology. Combined with the absence of UK marketing authorisation and missing safety/MOA data (flagged as a **Blocking** data gap in the evidence pack), there is no basis to proceed with this specific candidate.

**To proceed, the following is needed:**
- SmPC warnings, contraindications and DDI data (currently a Blocking data gap — DG001)
- Confirmed mechanism of action and original indication data for Meloxicam (DG002)
- UK marketing authorisation status verification
- **Suggested re-focus:** Ranks 6–8 in this evidence pack (spondyloarthropathy susceptibility, rheumatoid nodulosis, RF-positive polyarticular juvenile idiopathic arthritis) carry class-level mechanistic plausibility as inflammatory arthropathies consistent with NSAID/COX-2 pharmacology, and are scored at Evidence Level L4 with a "Research Question" recommendation — these merit evaluation ahead of the current top-ranked candidate.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

